{"preliminary_commentary":{"by_channel":{"x_thread":16,"youtube":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06176261\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["datopotamab deruxtecan"]],"indication":null,"name":"DATO-BASE","nct_id":"NCT06176261","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dato-base-nct06176261. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"24 participants will be enrolled and will complete study procedures as outlined below:\n\n* Baseline visit with optional CSF collection via lumbar puncture and assessments.\n* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.\n* Cycle 1 Through End of Treatment:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.\n* End of Treatment:\n\n  * Follow up every 6 months.\n  * Optional CSF collection via lumbar puncture.\n  * CT or MRI scans every 12 weeks.","label":"Cohort A: Estrogen Receptor Positive HER2-Negative Metastatic Breast Cancer","type":"EXPERIMENTAL"},{"description":"24 participants will be enrolled and will complete study procedures as outlined below:\n\n* Baseline visit with optional CSF collection via lumbar puncture and assessments.\n* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.\n* Cycle 1 Through End of Treatment:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.\n* End of Treatment:\n\n  * Follow up every 6 months.\n  * Optional CSF collection via lumbar puncture.\n  * CT or MRI scans every 12 weeks.","label":"Cohort B: Metastatic Triple-Negative Breast Cancer","type":"EXPERIMENTAL"},{"description":"* Baseline visit with CSF collection via lumbar puncture and assessments.\n* CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.\n* Cycle 1\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.\n* Cycle 2\n\n  * Day 1 of 21 day cycle: Predetermined dose of Dato-DXd 1x daily.\n  * Day 2 of 21 day cycle: CSF collection.\n* Cycle 3 Through End of Treatment:\n\n  --Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.\n* End of Treatment:\n\n  * Follow up every 6 months.\n  * Optional CSF collection via lumbar puncture.\n  * CT or MRI scans every 12 weeks.","label":"Cohort C: HER2-Negative Metastatic Breast Cancer (any ER Expression) with Leptomeningeal Metastases","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2029-01-01","type":"ESTIMATED"},"conditions":["Breast Cancer","Breast Cancer Female","Metastatic Triple-Negative Breast Carcinoma","ER Positive Breast Cancer","HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma","ER-negative Breast Cancer"],"enrollment":{"count":58,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Datopotamab Deruxtecan","otherNames":["DS-1062; DS-1062a, Dato-DXd"],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"Nancy Lin, MD","official_title":"DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) in RANO-BM Criteria","timeFrame":"3 years"}],"references":[],"start_date":{"date":"2024-01-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","url":"https://clinicaltrials.gov/study/NCT06176261"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dato-base-nct06176261"}